title: Evolution of bone marrow transplantation--the original immunotherapy.
abstract: Allogeneic bone-marrow transplantation (BMT) has provided a curative treatment option for chronic myeloid leukaemia (CML) over the past 20-30 years. New drugs - signal transduction inhibitors - that target the bcr-abl oncogene have the potential to render such transplantation procedures obsolete and provide hope for those without a suitable donor ( approximately 60% of patients). Here, we discuss how new drug and immune-based approaches could be combined to enhance treatment of this already 'curable' malignancy.
authors: Academic Transfusion Medicine Unit (ATMU), Dept of Medicine, Royal Infirmary, 10 Alexandra Parade, G31 2ER., Glasgow, UK.
authors: J D
authors: JD
authors: Campbell
authors: G
authors: G
authors: Cook
authors: T L
authors: TL
authors: Holyoake
mesh_terms: D016026:Bone Marrow Transplantation / Q000379:methods* / Q000639:trends*; D006801:Humans; D007167:Immunotherapy / Q000379:methods* / Q000639:trends*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy